Assessing Cancer Signal during Oral Antiplatelet Therapy in the Food and Drug Administration Adverse Event Reporting System: Mission Impossible

Whether aggressive prolonged dual antiplatelet therapy (DAPT) promotes solid cancer risks remains a critical unsolved issue. Since the evidence from randomized trials, affiliated U.S. Food and Drug Administration (FDA) reviews, meta-analyses, and national registries is mixed, the search is ongoing....

Descripción completa

Detalles Bibliográficos
Autores principales: Serebruany, Victor, Kim, Moo Hyun, Thevathasan, Christian, Marciniak, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2018
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524855/
https://www.ncbi.nlm.nih.gov/pubmed/31249926
http://dx.doi.org/10.1055/s-0037-1615253

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524855/
https://www.ncbi.nlm.nih.gov/pubmed/31249926
http://dx.doi.org/10.1055/s-0037-1615253

Ejemplares similares